In this issue:
Triplet-modality perioperative approach promising for resectable HER2-positive disease
Domvanalimab + zimberelimab combo has durable efficacy
Non-invasive blood-based assay may aid early detection of EAC
Anti-TIGIT + PD-L1 and chemo combo prolongs survival in OSCC
Addition of tezolizumab + tiragolumab to chemo boosts response rate
KEYNOTE-590 shows durable efficacy for pembrolizumab-chemo combo
Serum cytokines predict response and survival to CRT + anti-PD-1 in OSCC
Characterisation of T-DXd’s safety profile
Serum multiomics may predict prognosis and adverse reactions to CRT
Chemoimmunotherapy improves survival in real-world populations
Please login below to download this issue (PDF)